Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Citations
233 citations
204 citations
202 citations
196 citations
Cites background from "Ipilimumab and Stereotactic Radiosu..."
...Patel, 2017 (reF.(141)) Singleinstitution, retrospective study involving 54 patients with brain metastases from melanoma Intracranial SRT ± ipilimumab within 4 months (n = 20) TABN in 21% of patients receiving SRT versus 30% of patients receiving SRT + ipilimumab (P = 0....
[...]
168 citations
References
13,081 citations
"Ipilimumab and Stereotactic Radiosu..." refers background in this paper
...To investigate the efficacy of ipilimumab on intracranial disease, Margolin et al9 conducted a prospective nonrandomized phase II trial of ipilimumab alone for untreated MBM....
[...]
...2% and 0% of patients enrolled to the ipilimumab arms had stable MBM.(1,2) With up to 50% of melanoma patients developing brain metastasis (BM),(5,6) a poor prognostic indicator,(7) the efficacy of ipilimumab against MBM is a highly debated and clinically relevant question....
[...]
...Key Words: melanoma brain metastasis, stereotactic radiosurgery, ipilimumab (Am J Clin Oncol 2017;40:444–450) Antibodies targeting cytotoxic T-lymphocyte–associatedantigen 4, a T-cell inhibitory signaling molecule, have demonstrated improvements in overall survival (OS) at 3 years for metastatic melanoma patients in 2 randomized phase III.1,2 Distinct from chemotherapy or targeted agents, the survival rates stabilized after 2 years and remained durable at 5 years.3,4 These promising results led the FDA to approve anti-CTLA-4 antibody, ipilimumab, for metastatic melanoma....
[...]
...Antibodies targeting cytotoxic T-lymphocyte–associated antigen 4, a T-cell inhibitory signaling molecule, have demonstrated improvements in overall survival (OS) at 3 years for metastatic melanoma patients in 2 randomized phase III.(1,2) Distinct from chemotherapy or targeted agents, the survival rates stabilized after 2 years and remained durable at 5 years....
[...]
...In both of these phase III trials with ipilimumab, patients with melanoma brain metastasis (MBM) were poorly represented: only 12.2% and 0% of patients enrolled to the ipilimumab arms had stable MBM.1,2 With up to 50% of melanoma patients developing brain metastasis (BM),5,6 a poor prognostic indicator,7 the efficacy of ipilimumab against MBM is a highly debated and clinically relevant question....
[...]
4,069 citations
"Ipilimumab and Stereotactic Radiosu..." refers background in this paper
...To investigate the efficacy of ipilimumab on intracranial disease, Margolin et al9 conducted a prospective nonrandomized phase II trial of ipilimumab alone for untreated MBM....
[...]
...2% and 0% of patients enrolled to the ipilimumab arms had stable MBM.(1,2) With up to 50% of melanoma patients developing brain metastasis (BM),(5,6) a poor prognostic indicator,(7) the efficacy of ipilimumab against MBM is a highly debated and clinically relevant question....
[...]
...Key Words: melanoma brain metastasis, stereotactic radiosurgery, ipilimumab (Am J Clin Oncol 2017;40:444–450) Antibodies targeting cytotoxic T-lymphocyte–associatedantigen 4, a T-cell inhibitory signaling molecule, have demonstrated improvements in overall survival (OS) at 3 years for metastatic melanoma patients in 2 randomized phase III.1,2 Distinct from chemotherapy or targeted agents, the survival rates stabilized after 2 years and remained durable at 5 years.3,4 These promising results led the FDA to approve anti-CTLA-4 antibody, ipilimumab, for metastatic melanoma....
[...]
...Antibodies targeting cytotoxic T-lymphocyte–associated antigen 4, a T-cell inhibitory signaling molecule, have demonstrated improvements in overall survival (OS) at 3 years for metastatic melanoma patients in 2 randomized phase III.(1,2) Distinct from chemotherapy or targeted agents, the survival rates stabilized after 2 years and remained durable at 5 years....
[...]
...In both of these phase III trials with ipilimumab, patients with melanoma brain metastasis (MBM) were poorly represented: only 12.2% and 0% of patients enrolled to the ipilimumab arms had stable MBM.1,2 With up to 50% of melanoma patients developing brain metastasis (BM),5,6 a poor prognostic indicator,7 the efficacy of ipilimumab against MBM is a highly debated and clinically relevant question....
[...]
2,330 citations
"Ipilimumab and Stereotactic Radiosu..." refers background or methods in this paper
...7 months.(18) By activating immune cells, which can cross the BBB and target tumors, immunotherapy is a possible novel adjuvant approach against BM....
[...]
...Patient age, ECOG PS, and number of BM were classified into categories per previously published prognostic indices.(18) The number of BM was separated into categories of 1, 2 to 3, and Z4....
[...]
1,962 citations
"Ipilimumab and Stereotactic Radiosu..." refers background in this paper
...Furthermore, intracranial local control (LC) rate of 29% with ipilimumab alone was lower than the 67% to 75% LC rate with stereotactic radiation therapy (SRS).(10,11) With ipilimumab alone constrained by lower LC and higher intracranial progression, adding radiation is a potential treatment approach to help address these limitations....
[...]
1,769 citations
"Ipilimumab and Stereotactic Radiosu..." refers background in this paper
...Case reports combining high-dose, ablative radiation with concurrent ipilimumab have demonstrated durable systemic responses and higher than expected survival.(22,23) Because these case reports delivered concurrent ipilimumab and radiation, one possible explanation for the no improvement in survival is that timing of therapy may be critical to maximize the synergy between SRS and radiation....
[...]